Journal article Open Access
Gustavo A. A. dos Santos*; Paulo Celso Pardi
Objectives: To conduct a preliminary assessment of the effects of the oral and transdermal pharmaceutical forms of rivastigmine tartrate
Methods: Forty patients with AD were treated with cholinesterase inhibitors (ChE-Is), evaluated using the MMSE and NPI, and simultaneously sampled to determine their serum levels of AChE and BuChE for 180 days.
Results: The differences obtained between the oral and transdermal forms, as assessed by the MMSE and NPI scores of the AD patients, were not significantly different at the three time points examined (0, 90, and 180 days). However, the serum BuChE levels of the transdermal group were significantly different (p < 0.0004) than those of the oral group at 90 days.
Conclusion: The use of a transdermal ChE-I, rivastigmine tartrate, significantly reduced the levels of BuChE in the AD patients.